Timbercreek Financial (TF) EPS Estimated At $0.17; Clearside Biomedical (CLSD) Shorts Raised By 0.12%

April 17, 2018 - By Maria Brooks

Clearside Biomedical Inc (NASDAQ:CLSD) had an increase of 0.12% in short interest. CLSD’s SI was 1.51M shares in April as released by FINRA. Its up 0.12% from 1.51 million shares previously. With 708,000 avg volume, 2 days are for Clearside Biomedical Inc (NASDAQ:CLSD)’s short sellers to cover CLSD’s short positions. The SI to Clearside Biomedical Inc’s float is 8.2%. The stock increased 6.56% or $0.69 during the last trading session, reaching $11.21. About 239,680 shares traded. Clearside Biomedical, Inc. (NASDAQ:CLSD) has risen 41.83% since April 17, 2017 and is uptrending. It has outperformed by 30.28% the S&P500.

Analysts expect Timbercreek Financial Corporation (TSE:TF) to report $0.17 EPS on May, 3.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.17 EPS. T_TF’s profit would be $13.46M giving it 13.50 P/E if the $0.17 EPS is correct. After having $0.17 EPS previously, Timbercreek Financial Corporation’s analysts see 0.00% EPS growth. The stock increased 0.11% or $0.01 during the last trading session, reaching $9.18. About 16,190 shares traded. Timbercreek Financial Corporation (TSE:TF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Timbercreek Financial Corporation, a non-bank commercial real estate lender, provides shorter-duration structured financing solutions to commercial real estate investors in Canada. The company has market cap of $727.05 million. It focuses on lending against income-producing real estate properties, such as multi-residential, office, and retail buildings located in urban markets. It has a 13.11 P/E ratio.

Among 3 analysts covering Timbercreek Financial (TSE:TF), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Timbercreek Financial had 5 analyst reports since November 11, 2016 according to SRatingsIntel. The company was maintained on Friday, November 11 by TD Securities. National Bank Canada maintained the stock with “Outperform” rating in Wednesday, November 16 report. The company was maintained on Friday, March 3 by Raymond James. TD Securities maintained the stock with “Hold” rating in Thursday, March 2 report.

Among 4 analysts covering Clearside Biomedical (NASDAQ:CLSD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Clearside Biomedical had 5 analyst reports since June 27, 2016 according to SRatingsIntel. The firm has “Outperform” rating by Cowen & Co given on Monday, June 27. The stock of Clearside Biomedical, Inc. (NASDAQ:CLSD) earned “Buy” rating by Stifel Nicolaus on Monday, October 24. The firm earned “Outperform” rating on Monday, June 27 by Wedbush. The rating was initiated by Needham with “Buy” on Tuesday, June 28. The rating was initiated by Stifel Nicolaus with “Buy” on Monday, June 27.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts